Treace Medical Concepts (TMCI) announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (ZBH), alleging infringement of 4 patents related to Treace’s innovative Lapiplasty 3D Bunion Correction technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. “Treace Medical was the first company to develop, patent, and introduce an instrumented 3D bunion correction system for true tri-planar lapidus bunion correction and is the recognized leader in the surgical treatment of bunions. We believe that this lawsuit is necessary to protect the significant investments we have made in our pioneering research and technology, which is in the best interest of our stockholders,” said John T. Treace, Chairman, CEO and Founder of Treace. “Enforcing and defending our intellectual property helps to drive our ability to continue to innovate solutions that benefit patients.” Treace’s patent portfolio includes 80 granted U.S. patents, with an additional 26 granted patents worldwide and over 150 pending patent applications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- TMCI Lawsuit Alert! Class Action Lawsuit Against Treace Medical Concepts
- Treace Medical Elects Directors at Annual Meeting
- Treace Medical Concepts’ Earnings Call: Balancing Growth and Challenges
- Treace Medical price target lowered to $8.60 from $10 at UBS
- Cautious Hold Rating for Treace Medical Concepts Amid Mixed Outlook and Revenue Uncertainty